This study is in progress, not accepting new patients
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSF
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- ID
- NCT04060342
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 242 study participants
- Last Updated